Embedded Files
Published human pharmacokinetic evidence
Published human pharmacokinetic evidence
Scout begins with an unusually advanced starting point.
Research. $3M in historical R&D investment and five years of laboratory development
Platform. Patent-pending formulation technology supported by proprietary data, methods, and know-how.
Human evidence. A Scout formulation was evaluated in a published Phase 1 human pharmacokinetic study.
PK performance. The study reported 1.48× AUC₀₋₁₂ versus comparator transport oil, with Tₘₐₓ decreasing from 4.2 to 1.6 hours.
Formulate, validate, license
Formulate, validate, license
Scout seeks a focused role in pharmaceutical value creation.
Select high-value formulation opportunities.
Develop and validate proprietary formulations.
Strengthen Intellectual property with molecule-specific data.
License technology to partners with paid feasibility studies and royalties.
A capital-efficient model designed to create value before late-stage development and commercialization.
Built for pharmaceutical partnerships
Built for pharmaceutical partnerships
Scout combines a substantial technical history with a newly organized corporate structure.
Delaware C-Corporation formed in August 2026
Five years and $3M of prior R&D already Invested In the technology.
Intellectual property fully assigned to Scout, with sole-Inventorship.
Asset-light structure built for licensing rather than commercial drug infrastructure.
A focused company designed to develop, protect, and license formulation assets.
Google Sites
Report abuse